Page last updated: 2024-08-24

fluorodeoxyglucose f18 and hki 272

fluorodeoxyglucose f18 has been researched along with hki 272 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bryce, R; Dujka, M; Hyman, DM; Jhaveri, K; Mann, G; Mayer, I; Meric-Bernstam, F; Piha-Paul, SA; Quinn, D; Saura, C; Shahin, S; Solit, DB; Stone, B; Ulaner, GA	1

Trials

1 trial(s) available for fluorodeoxyglucose f18 and hki 272

Article	Year
Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 12-15, Volume: 25, Issue:24 Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Breast Neoplasms, Male; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Patient Selection; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinolines; Radiopharmaceuticals; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Treatment Outcome	2019

Article

Year

Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 12-15, Volume: 25, Issue:24

Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Breast Neoplasms, Male; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Patient Selection; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinolines; Radiopharmaceuticals; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Treatment Outcome

2019